Trial reportEuropean heart journal2010
Fasting plasma glucose in non-diabetic participants and the risk for incident cardiovascular events, diabetes, and mortality: results from WOSCOPS 15-year follow-up.
Trial report in European heart journal, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Markers of dysglycaemia and risk of coronary heart disease in people without diabetes: Reykjavik prospective study and systematic review.PLoS medicine · 2010Pooled it
- Mortality and morbidity during and after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.Journal of clinical hypertension (Greenwich, Conn.) · 2012Trial
- Preconception hypoglycemia and adverse pregnancy outcomes in Chinese women aged 20-49 years: A retrospective cohort study in China.PLoS medicine · 2025Article
- Association between fasting glucose/high-density lipoprotein cholesterol ratio and cardiovascular disease risk in Chinese middle-aged and older adults: a longitudinal study.Frontiers in cardiovascular medicine · 2025Article
- Associations of fasting plasma glucose with all-cause mortality and cardiovascular events in older Chinese diabetes patients: A population-based cohort study.Journal of diabetes investigation · 2024Article
- Association of longitudinal trajectories of fasting plasma glucose with all-cause and cardiovascular mortality among a Chinese older population: a retrospective cohort study.BMC public health · 2024Article
- Association of fasting plasma glucose trajectory with lifetime risk of cardiovascular disease.European journal of clinical nutrition · 2023Article
- Causal Association of Type 2 Diabetes Mellitus and Glycemic Traits With Cardiovascular Diseases and Lipid Traits: A Mendelian Randomization Study.Frontiers in endocrinology · 2022Article
- Antipsychotic-Related Risks of Type 2 Diabetes Mellitus in Enrollees With Schizophrenia in the National Basic Public Health Service Program in Hunan Province, China.Frontiers in psychiatry · 2022Article
- Fasting glucose level and all-cause or cause-specific mortality in Korean adults: a nationwide cohort study.The Korean journal of internal medicine · 2021Article
- Long-term tracking of fasting blood glucose variability and peripheral artery disease in people without diabetes.BMJ open diabetes research & care · 2020Article
- Association of Low Fasting Glucose and HbA1c With Cardiovascular Disease and Mortality: The MESA Study.Journal of the Endocrine Society · 2019Article
- A prospective study of low fasting glucose with cardiovascular disease events and all-cause mortality: The Women's Health Initiative.Metabolism: clinical and experimental · 2017Article
- Time-saving screening for diabetes in patients with coronary artery disease: a report from EUROASPIRE IV.BMJ open · 2016Article
- Contrasting associations of insulin resistance with diabetes, cardiovascular disease and all-cause mortality in the elderly: PROSPER long-term follow-up.Diabetologia · 2014Article
- Individuals with prediabetes identified by HbA1c undergoing coronary angiography have worse cardiometabolic profile than those identified by fasting glucose.Diabetology & metabolic syndrome · 2014Article
- Revisiting the links between glycaemia, diabetes and cardiovascular disease.Diabetologia · 2013 · on this mapReview
- N-terminal pro-B-type natriuretic peptide and the prediction of primary cardiovascular events: results from 15-year follow-up of WOSCOPS.European heart journal · 2013Article
- Fasting glucose, obesity, and coronary artery calcification in community-based people without diabetes.Diabetes care · 2012Article
- Comparison of HbA1c and oral glucose tolerance test for diagnosis of diabetes in patients with coronary artery disease.Clinical research in cardiology : official journal of the German Cardiac Society · 2012Article
Corrections and comments
- Commented on by
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
aimsThe evidence base for fasting plasma glucose (FPG) in the non-diabetic range as a risk factor for cardiovascular disease (CVD) is inconclusive. We investigated this question in the West of Scotland Coronary Prevention Study (WOSCOPS). METHODS AND
resultsIn WOSCOPS, we related FPG in 6447 men (mean age 55 years) with hypercholesterolaemia, but no history of CVD or diabetes, to the risk of cardiovascular events and mortality over 14.7 years of follow-up; 2381 non-fatal/fatal cardiovascular events and 1244 deaths occurred. Participants were divided into fifths of baseline FPG, Q1 (< or =4.3 mmol/L) to Q5 (>5.1-6.9 mmol/L). Q2 was designated the referent based on previous studies which have suggested a J-shaped relationship between FPG and CVD. Compared with Q2 (>4.3-4.6 mmol/L), men in Q5 had no elevated risk for cardiovascular events [hazard ratio (HR) 0.95 (0.83-1.08)], or all-cause mortality [HR 0.96 (0.80-1.15)] in fully adjusted analyses despite a significant risk for incident diabetes [HR 22.05 (10.75-45.22)]. After further dividing Q5 into fifths, Q5a-e, individuals in Q5e (FPG 5.8-6.9 mmol/L) were also not at increased risk of cardiovascular events [HR 1.05 (0.82-1.35)] or other endpoints compared with Q2. All results were similar using Q1 as the referent.
conclusionElevations in FPG in the non-diabetic range were not associated with long-term risk of cardiovascular events in middle-aged men in WOSCOPS. These data suggest that the current FPG cutoff for diagnosing diabetes also appropriately identifies western men at risk of CVD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.